Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1439

Sort by

Sort Order Select

Journal Articles

Dose-Intensification in Early Unfavorable Hodgkin Lymphoma: Long-Term Follow up of the German Hodgkin Study Group (GHSG) HD14 Trial

Sarah Gillessen, MD, Annette Plütschow, Michael Fuchs, MD, Jana Markova, MD, Richard Greil, MD, Max S. Topp, MD, Julia Meissner, MD, Josée M Zijlstra, MD PhD, Dennis A. Eichenauer, Volker Diehl, MD, Peter Borchmann, MD PhD, Andreas Engert, MD, Bastian von Tresckow, MD

Blood (2019) 134 (Supplement_1): 129.

https://doi.org/10.1182/blood-2019-125249

Published: 2019

Journal Articles

Excellent Overall Survival and Low Incidence of Late Effects in Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Sickle Cell Disease: A Report from the Center for International Blood and Marrow Transplant Research (CIBMTR)

Elizabeth Stenger, MD, Rachel Phelan, MDMPH, Bronwen E. Shaw, MD PhD, Minoo Battiwalla, MD, Stephanie Bo-Subait, MPH, Ruta Brazauskas, PhD, David K. Buchbinder, MD MSHS, Betty K. Hamilton, MD, Shalini Shenoy, MD, Lakshmanan Krishnamurti, MD

Blood (2019) 134 (Supplement_1): 697.

https://doi.org/10.1182/blood-2019-128797

Published: 2019

Journal Articles

Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 ( IDH2 ) Mutations: Interim Phase II Results from an Ongoing, Randomized Study

Courtney D. DiNardo, MD MSc, Andre C. Schuh, MD, Eytan M. Stein, MD, Pau Montesinos Fernandez, MD PhD, Andrew Wei, MBBS, FRACP, FRCPA, PhD, Stephane De Botton, Amer M. Zeidan, MBBS, MHS, Amir T. Fathi, MD, Lynn Quek, MD PhD, Hagop M. Kantarjian, MD, Mark G. Frattini, MD, Frederik Lersch, RN, Jing Gong, PhD, Aleksandra Franovic, PhD, Kyle MacBeth, PhD, Paresh Vyas, MD PhD, Hartmut Döhner, MD

Blood (2019) 134 (Supplement_1): 643.

https://doi.org/10.1182/blood-2019-130362

Published: 2019

Journal Articles

Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR)

Blood (2019) 134 (Supplement_1): 287.

https://doi.org/10.1182/blood-2019-127516

Published: 2019

Journal Articles

Are Racial Disparities in Acute Myeloid Leukemia (AML) Clinical Trial Enrollment Associated with Comorbidities and/or Organ Dysfunction?

Abby Statler, PhD MPH, Brian P. Hobbs, PhD, Tomas Radivoyevitch, PhD, Sudipto Mukherjee, MD PhD MPH, Kimberly Bell, MBA, RN, BSN, Anjali S. Advani, MD, Aaron T. Gerds, MD MS, Aziz Nazha, MD, Bhumika J. Patel, MD, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS

Blood (2019) 134 (Supplement_1): 381.

https://doi.org/10.1182/blood-2019-129096

Published: 2019

Journal Articles

Impact of FLT3 -ITD Remission Depth in Acute Myeloid Leukemia Patients Prognosis Prediction before Allogeneic Hematopoietic Cell Transplantation

Xiaoyu Xu, Hongjie Shen, Jia Chen, Xiaowen Tang, Shengli Xue, Xu Yang, Qiaocheng Qiu, Zixuan Ding, Suning Chen, Depei Wu, MD PhD

Blood (2019) 134 (Supplement_1): 262.

https://doi.org/10.1182/blood-2019-130381

Published: 2019

Journal Articles

Incidence of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Including CNS Relapse in a Population-Based Cohort of 4205 Patients in Sweden

Sara Harrysson, MD, Sandra Eloranta, Sara Ekberg, Gunilla Enblad, Mats Jerkeman, MD Professor, Sverker Hasselblom, Björn E Wahlin, MD PhD, Per-Ola Andersson, MD PhD, Karin E. Smedby, MD PhD

Blood (2019) 134 (Supplement_1): 399.

https://doi.org/10.1182/blood-2019-122014

Published: 2019

Journal Articles

Real-World Outcome for Newly Diagnosed Patients with Functional High-Risk Myeloma - a Myeloma and Related Diseases Registry Analysis

Andrew Spencer, MBBS, FRACP, FRCPA, DM, Peter Mollee, MBBS, MMSc, FRACP, FRCPA, Hilary Anne Blacklock, FRACP, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Hang Quach, MBBS, FRACP, FRCPA, MD, P. Joy Ho, MBBS DPhil FRACP FRCPA, Ruth Spearing, MD, Jay Hocking, MBBS, FRACP, FRCPA, Bradley Augustson, MBBS FRACP FRCPA, H. Miles Prince, MBBS (Hons), MD FRACP, FRCPA, AFRCMA, MACD, Elizabeth M. Moore, PhD, Zoe McQuilten, Erica M. Wood, MBBS, FRACP, FRCPA, Cameron Wellard

Blood (2019) 134 (Supplement_1): 269.

https://doi.org/10.1182/blood-2019-129431

Published: 2019

Journal Articles

Impact of Depth of Pretransplant Clinical Response on Outcomes of Acute Myeloid Leukemia Patients in First Complete Remission (AML-CR1) Who Undergo Allogeneic Hematopoietic Cell Transplantation (AlloHCT)

Mary-Elizabeth M. Percival, MD, Hai-Lin Wang, MPH, Mei-Jie Zhang, PhD, Elihu H. Estey, MD, Mark Litzow, MD, Partow Kebriaei, MD, Marcos de Lima, MD, Wael Saber, MD MS, Daniel J. Weisdorf, MD, Brenda M Sandmaier, MD

Blood (2019) 134 (Supplement_1): 4585.

https://doi.org/10.1182/blood-2019-123510

Published: 2019

Journal Articles

Impact of Minimal Residual Disease Detected By Multiparameter Flow Cytometry on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia Patients in First Complete Remission

Zoya V. Konova, Elena N. Parovichnikova, MD PhD, Irina V. Galtseva, MD PhD, Nikolay M. Kapranov, Julia O. Davydova, Mikhail Yu. Drokov, MD PhD, Maria V. Nareyko, MD, Natalia N. Popova, MD, Anna A. Dmitrova, MD, Ulyana V. Maslikova, MD, Olga S. Starikova, MD, Ekaterina I. Usikova, MD, Ekaterina D. Mikhaltsova, MD PhD, Olga M. Koroleva, MD, Vera A. Vasilyeva, MD PhD, Tatiana I. Lobanova, MD, Larisa A. Kuzmina, MD PhD, Valeriy G. Savchenko, MD PhD

Blood (2019) 134 (Supplement_1): 4562.

https://doi.org/10.1182/blood-2019-123528

Published: 2019

Journal Articles

Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma

Blood (2019) 134 (Supplement_1): 4386.

https://doi.org/10.1182/blood-2019-130771

Published: 2019

Journal Articles

Changing the Fate of Children with Acute Lymphoblastic Leukemia (ALL) in a Limited Resources Setting

Yajaira Valentine Jimenez-Antolinez, MD, Julia Esther Colunga Pedraza, MD, José Eduardo Mares-Gil, MD, Emma Lizeth Estrada, MD, Jesus Mauricio Gonzalez-Diaz, David Gomez-Almaguer, MD, Oscar Gonzalez Llano, MD

Blood (2019) 134 (Supplement_1): 5075.

https://doi.org/10.1182/blood-2019-132205

Published: 2019

Journal Articles

Depth of Pre-Treatment Immunoparesis Is an Important Prognostic Factor for Survival in Relapsed Multiple Myeloma

Rajshekar Chakraborty, MD, Lisa Rybicki, MS, Megan Nakashima, MD, Robert M. Dean, MD, Beth M. Faiman, PhDCNP, Christy J. Samaras, DO, Nathaniel Rosko, PharmD, Jason Valent, MD, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 4359.

https://doi.org/10.1182/blood-2019-123861

Published: 2019

Journal Articles

Therapy Related Myeloid Neoplasms- Clinical, Pathologic and Genetic Characteristics - a Single Center Experience

Dina Sameh Soliman, MD MB, MMSc, Ahmed Al-Sabbagh, MD, Shehab Fareed Mohamed, MD, Susanna Jane Akiki, PhD, Halima El-Omri, MD, Firyal Ibrahim, MD, Mohamed A Yassin, MBBS, MSc, Prem Chandra, PhD

Blood (2019) 134 (Supplement_1): 5169.

https://doi.org/10.1182/blood-2019-124951

Published: 2019

Journal Articles

Comparison of Allogeneic Transplant Outcomes Using Conditioning with Different Dose of Busulfan for Children with Acute Myeloid Leukemia

Olesia V Paina, PhD, Zhemal Zarifovna Rakhmanova, Dr., Polina Valerievna Kozhokar, Dr., Anastasia S Frolova, Dr, Kirill Alexandrovich Ekushov, Dr., Luibov Tsvetkova, Tatiana A Bykova, MD PhD, Inna V Markova, Dr., Sergey N. Bondarenko, PhDMD, Ildar M Barkhatov, MD PhD, Aleksandr Alyanski, Elena Babenko, Ivan S Moiseev, MD PhD, Marina O Popova, MD PhD, Elena Vladimirovna Semenova, MD PhD, Ludmila S Zubarovskaya, MD PhD professor, Axel Zander, Boris Afanasyev

Blood (2019) 134 (Supplement_1): 4510.

https://doi.org/10.1182/blood-2019-128155

Published: 2019

Journal Articles

Interactions between Donor Activating Killer Immunoglobulin-like Receptors (KIRs) and Somatic Mutations and Their Association with Outcomes after Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia (AML)

Blood (2019) 134 (Supplement_1): 4599.

https://doi.org/10.1182/blood-2019-131011

Published: 2019

Journal Articles

Autologous Stem Cell Transplantation in Mantle Cell Lymphoma - Selection Mechanisms and Survival By Age Group

Ingrid Glimelius, MD PhD, Karin E. Smedby, MD PhD, Alexandra Albertsson-Lindblad, MD PhD, Sandra Eloranta, Mats Jerkeman, MD Professor, Caroline Weibull

Blood (2019) 134 (Supplement_1): 4572.

https://doi.org/10.1182/blood-2019-124676

Published: 2019

Journal Articles

Outcomes and Factors Impacting Use of Axicabtagene Ciloleucel in Refractory and Relapsed Large B-Cell Lymphoma: An Intent-to-Treat Analysis

Agrima Mian, MBBS, MD, Wei Wei, MS, Allison M. Winter, MD, Jack Khouri, MD, Deepa Jagadeesh, MDMPH, Faiz Anwer, MD, Aaron T. Gerds, MD MS, Robert M. Dean, MD, Ronald Sobecks, MD, Brad Pohlman, MD, Matt Kalaycio, MD, Betty K. Hamilton, MD, Navneet S. Majhail, MD MS, Brian T. Hill, MD

Blood (2019) 134 (Supplement_1): 4452.

https://doi.org/10.1182/blood-2019-127087

Published: 2019

Journal Articles

Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Retrospective, Single-Institution Analysis Based on Risk Features and Debulking Strategy with Anti-CD20 Monoclonal Antibody

Ariel F Grajales-Cruz, MD, Julio Chavez, Virginia Olivia Volpe, MD, Jose Sandoval-Sus, MD, Bijal Shah, MD, Celeste Bello, MD, Lubomir Sokol, MD PhD, Shanel Fisher, Rajesh R Nair, PhD, Yun Seongseok, MD, Hayder Saeed, MD, Leidy Isenalumhe, MD, Elyce P. Turba, MSN, RN, Lisa Nodzon, PhD ARNP, AOCNP, Javier Pinilla Ibarz, MD PhD

Blood (2019) 134 (Supplement_1): 5484.

https://doi.org/10.1182/blood-2019-129260

Published: 2019

Journal Articles

Clinical Outcomes of Obinutuzumab Therapy across Non-Hodgkin Lymphoma Subtypes

Mitchell E. Hughes, PharmD, Esin C. Namoglu, B.S., Connie Suen, PharmD, Stephen J Schuster, MD, Jakub Svoboda, MD, Daniel J. Landsburg, MD, Stefan K. Barta, MD MRCP, MS, James N. Gerson, MD, Kyle Robinson, MD, Elise A. Chong, MD, Joanna M Rhodes, MD, Emily C. Ayers, MD, Alison W. Loren, MD MSCE, Edward A. Stadtmauer, MD FACP, Sunita Dwivedy Nasta, MD

Blood (2019) 134 (Supplement_1): 5247.

https://doi.org/10.1182/blood-2019-128148

Published: 2019

NARROW

Dose-Intensification in Early Unfavorable Hodgkin Lymphoma: Long-Term Follow up of the German Hodgkin Study Group (GHSG) HD14 Trial

Excellent Overall Survival and Low Incidence of Late Effects in Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Sickle Cell Disease: A Report from the Center for International Blood and Marrow Transplant Research (CIBMTR)

Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 ( IDH2 ) Mutations: Interim Phase II Results from an Ongoing, Randomized Study

Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR)

Are Racial Disparities in Acute Myeloid Leukemia (AML) Clinical Trial Enrollment Associated with Comorbidities and/or Organ Dysfunction?

Impact of FLT3 -ITD Remission Depth in Acute Myeloid Leukemia Patients Prognosis Prediction before Allogeneic Hematopoietic Cell Transplantation

Incidence of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Including CNS Relapse in a Population-Based Cohort of 4205 Patients in Sweden

Real-World Outcome for Newly Diagnosed Patients with Functional High-Risk Myeloma - a Myeloma and Related Diseases Registry Analysis

Impact of Depth of Pretransplant Clinical Response on Outcomes of Acute Myeloid Leukemia Patients in First Complete Remission (AML-CR1) Who Undergo Allogeneic Hematopoietic Cell Transplantation (AlloHCT)

Impact of Minimal Residual Disease Detected By Multiparameter Flow Cytometry on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia Patients in First Complete Remission

Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma

Changing the Fate of Children with Acute Lymphoblastic Leukemia (ALL) in a Limited Resources Setting

Depth of Pre-Treatment Immunoparesis Is an Important Prognostic Factor for Survival in Relapsed Multiple Myeloma

Therapy Related Myeloid Neoplasms- Clinical, Pathologic and Genetic Characteristics - a Single Center Experience

Comparison of Allogeneic Transplant Outcomes Using Conditioning with Different Dose of Busulfan for Children with Acute Myeloid Leukemia

Interactions between Donor Activating Killer Immunoglobulin-like Receptors (KIRs) and Somatic Mutations and Their Association with Outcomes after Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia (AML)

Autologous Stem Cell Transplantation in Mantle Cell Lymphoma - Selection Mechanisms and Survival By Age Group

Outcomes and Factors Impacting Use of Axicabtagene Ciloleucel in Refractory and Relapsed Large B-Cell Lymphoma: An Intent-to-Treat Analysis

Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Retrospective, Single-Institution Analysis Based on Risk Features and Debulking Strategy with Anti-CD20 Monoclonal Antibody

Clinical Outcomes of Obinutuzumab Therapy across Non-Hodgkin Lymphoma Subtypes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only